Bacs-Kiskun Varmegyei Oktatokorhaz
- Address
- Nyiri Ut 38, 6000 Kecskemét, Hungary
Bacs-Kiskun Varmegyei Oktatokorhaz - Comprehensive Oncology and Cardiovascular Research Center
Bacs-Kiskun Varmegyei Oktatokorhaz is a leading clinical research institution specializing in advanced cancer therapeutics and cardiovascular disease management. The center demonstrates extensive expertise in immunotherapy-based oncology trials, with particular focus on novel checkpoint inhibitor combinations and antibody-drug conjugates across multiple solid tumor types. Their research portfolio encompasses breakthrough studies in triple-negative breast cancer, hormone receptor-positive breast cancer, lung cancer (both small cell and non-small cell), and urogenital malignancies including bladder, renal, and prostate cancers.
- Advanced Oncology: Phase III trials in breast cancer, lung cancer, bladder cancer, and gastrointestinal malignancies using pembrolizumab-based regimens and novel targeted therapies
- Cardiovascular Disease: Major outcome studies in acute myocardial infarction and heart failure with reduced ejection fraction, including innovative self-administered therapies
- Immunotherapy Combinations: Comprehensive research in immune checkpoint inhibitors combined with chemotherapy, targeted agents, and novel immunomodulators across multiple cancer types
- Rare Conditions and Preventive Medicine: Studies in alopecia areata, RSV prevention in pediatric populations, and lipoprotein disorders
The center demonstrates significant expertise in evaluating combination immunotherapy strategies, conducting complex biomarker-driven trials, and assessing next-generation therapeutics including antibody-drug conjugates like datopotamab deruxtecan and sacituzumab govitecan. Their cardiovascular research program includes innovative approaches to acute coronary syndrome management and chronic heart failure treatment, positioning them at the forefront of both oncology and cardiology clinical investigation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 15 therapeutic areas and 15 of 204 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 202 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
- 1Merck Sharp & Dohme LLC12active
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC29trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bacs-Kiskun Varmegyei Oktatokorhaz
lock Showing 1 of 122 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 204 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 32 | Unknown | 2018-08-24 | 2026-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.